Sino Biopharmaceutical (HKG:1177) said the enrollment of all subjects for a phase III clinical trial of TQC3721 inhalation suspension has been completed.
The drug was developed by unit Chia Tai Tianqing Pharmaceutical Group for the maintenance treatment of chronic obstructive pulmonary disease, a Thursday bourse filing showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.